We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Apenas manchetes de alto sinal — eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Healthcare apparel company Figs (NYSE:FIGS) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 28% year on year to $159.9 million. Its non-GAAP profit of $0.03 per share was $0.01 above analysts’ consensus estimates.
Figs delivered first quarter results that exceeded Wall Street’s expectations for both revenue and profitability, with management highlighting broad-based product strength and continued growth in new and returning customers. However, the market reacted negatively, with concerns centering on customer acquisition dynamics and external cost pressures. CEO Trina Spear cited “accelerating active customer growth” and successful product launches, but also acknowledged headwinds tied to tariffs and risi
FIGS, Inc. (NYSE:FIGS) is one of the 8 Best Small Cap US Stocks to Buy. On May 7, 2026, FIGS, Inc. (NYSE:FIGS) reported Q1 EPS of 3c, versus the consensus estimate of 2c. Revenue totaled $159.9M, versus the consensus estimate of $153.14M. Active customers as of March 31 increased 12.2% year over year to 3.0M, […]
Shares of healthcare apparel company Figs (NYSE:FIGS) fell 26.1% in the afternoon session after its first-quarter earnings report, despite beating Wall Street expectations, failed to impress investors.
FIGS (NYSE:FIGS) reported stronger-than-expected first-quarter fiscal 2026 results, with executives pointing to accelerating customer growth, broad demand across product categories and continued momentum in international markets and physical retail. Co-Founder and Chief Executive Officer Trina Spea
The latest analyst update on FIGS lifts the fair value estimate from $16.31 to $17.75, signaling a modest reset in what some see as a reasonable long term target for the stock. This shift lines up with commentary that mixes optimism around growth drivers and execution with caution on margins and how much recent performance is already reflected in the valuation. As you read on, you will see how these changing assumptions and viewpoints may shape the evolving FIGS story and what to watch...
FIGS is off to an incredible start to the year, sustaining last year's strong momentum with broad-based strength across all aspects of our business. Net revenues exceeded expectations, growing 28% year-over-year, driven by accelerating active customer growth. Importantly, this performance was driven by continued strength in our core U.S. e-commerce business even as our market expansion drivers of international community hubs and teams continue to scale.
Figs earnings weren't nearly as bad as you think -- but its stock is still very expensive.
Moby summary of FIGS, Inc.'s Q1 2026 earnings call
Dow Jones futures: President Donald Trump says a U.S.-Iran ceasefire is intact despite clashes. Rocket Lab, Cloudflare and IREN are big earnings movers.
Figs (FIGS) delivered earnings and revenue surprises of +125.56% and +5.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
The headline numbers for Figs (FIGS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Iran deal doubts hit stocks Thursday, but Nvidia, Tesla were strong. CoreWeave, Rocket Lab, Cloudflare were earnings movers late. The jobs report is on deck.
Healthcare apparel company Figs (NYSE:FIGS) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 28% year on year to $159.9 million. Its GAAP profit of $0.03 per share was $0.01 above analysts’ consensus estimates.
FIGS, GAP and CPRI enter the earnings season with strong momentum, margin discipline and positive ESPs, signaling potential earnings surprises.
Recently, commentary on FIGS highlighted that the healthcare apparel company has delivered relatively modest multi-year revenue growth, shrinking earnings per share and an outlook for flat free cash flow margins, suggesting it is losing ground to competitors. At the same time, a Form 144 filing revealed insider Sarah Oughtred plans to sell shares acquired through vested equity awards, a move that does not dilute existing shareholders but may focus investors on the company’s current operating...
The consensus price target hints at a 27.1% upside potential for Figs (FIGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Consumer discretionary businesses are levered to the highs and lows of economic cycles. Thankfully for the industry, demand trends seem to be healthy as discretionary stocks have gained 7.5% over the past six months. This performance has nearly mirrored the S&P 500.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
BLDR Q1 EPS misses estimates as sales fall 10%. Sales, however, beat forecasts. The new 2026 outlook turns cautious while buybacks expand.
UPBD Q1 earnings beat on Brigit subscriber growth, margin expansion and strong cash flow, even as revenues slightly miss estimates.
BKNG's Q1 surge was fueled by booming merchant revenues, but a softer Q2 outlook signals slowing momentum.